Abstract
4/2016
vol. 20
Original paper
Primary mediastinal B-cell lymphoma – metabolic and anatomical features in 18FDG-PET/CT and response to therapy
Contemp Oncol (Pozn) 2016; 20 (4): 297-301
Online publish date: 2016/09/05
Aim of the study: Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL).
Material and methods: Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy. The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis).
Results: Patients (five females, two males, average age 26.2 years, range 18–40 years), in clinical stage IIBX at diagnosis, were treated with eight cycles of R-CHOP-14 regimen, with radiotherapy consolidation (7/7) and central nervous system prophylaxis (6/7). The observed decrease in tumour volume between the initial staging and the interim PET ranged 72–89%. The mean ∆SUVmax reduction between initial (when available) and interim PET was 87% (range 84–89%). In 3/7 cases in the interim PET/CT, the uptake of the tumour was higher than the liver (Deauville Criteria score 4–5), and in 4/7 it was lower than the liver but higher than mediastinal blood pool structures (score 3 according to Deauville Criteria). After a median follow-up of 58 months – OS and EFS is 100%.
Conclusions: The excellent clinical outcome in the study group corresponds with very good metabolic and volumetric response in the interim PET. The ∆SUVmax seems to be easier in implementation and has a more significant impact than other measurements.
Material and methods: Retrospective analysis of seven PMBCL patients, treated at the University Hospital in Krakow, with interim PET/CT after the third course of chemo-immunotherapy. The analysis was based on the calculation of exact tumour volume and metabolic activity, compared with initial values (directly after diagnosis).
Results: Patients (five females, two males, average age 26.2 years, range 18–40 years), in clinical stage IIBX at diagnosis, were treated with eight cycles of R-CHOP-14 regimen, with radiotherapy consolidation (7/7) and central nervous system prophylaxis (6/7). The observed decrease in tumour volume between the initial staging and the interim PET ranged 72–89%. The mean ∆SUVmax reduction between initial (when available) and interim PET was 87% (range 84–89%). In 3/7 cases in the interim PET/CT, the uptake of the tumour was higher than the liver (Deauville Criteria score 4–5), and in 4/7 it was lower than the liver but higher than mediastinal blood pool structures (score 3 according to Deauville Criteria). After a median follow-up of 58 months – OS and EFS is 100%.
Conclusions: The excellent clinical outcome in the study group corresponds with very good metabolic and volumetric response in the interim PET. The ∆SUVmax seems to be easier in implementation and has a more significant impact than other measurements.
Keywords
lymphoma, large B-cell, diffuse/radionuclide imaging, tomography, X-ray computed mediastinal neoplasms/radiography
Coverage in
Indexed in
Integrated with
